| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland.
PURPOSE. Although malignant uveal melanoma disseminates predominantly hematogenously because of the absence of intraocular lymphatics, consensus about prognostic impact of microvascular density (MVD) has not been reached. This study was undertaken to investigate whether MVD, microvascular patterns, or both determine prognosis of uveal melanoma.
METHODS. A population-based retrospective cohort study of melanoma-specific and
all-cause mortality of 167 consecutive patients who had an eye
enucleated because of choroidal or ciliary body melanoma from 1972
through 1981 was conducted. MVD was determined by counting tumor
vessels in a masked fashion from areas of highest vessel density after
immunostaining for CD34 epitope, factor VIII-related antigen
(FVIII-RAg), and 
-smooth muscle actin (SMA). Kaplan–Meier and Cox
regression analyses of survival were performed. The association between
MVD and tumor size and location, cell type, and microvascular patterns
was assessed.
RESULTS. MVD could be determined from 134 of 167 melanomas (80%). Based on globally highest count obtained with antibodies to CD34, MVD ranged from 5 to 121 vessels/0.313 mm2 (median, 40) and its association with presence of microvascular loops and networks (P = 0.0006), epithelioid cells (P = 0.028), and largest basal tumor diameter (P = 0.0029) was statistically significant. The 10-year melanoma-specific mortality increased with MVD (0.09, 0.29, 0.59, and 0.64, according to quartiles; P < 0.0001), as did all-cause mortality (P = 0.0022). Equivalent results were obtained with immunostaining for FVIII-RAg, whereas MVD obtained with antibodies to SMA was not associated with prognosis. Cox regression showed a hazard ratio of 2.45 (95% CI, 1.43–4.18) for presence of epithelioid cells, 1.11 (95% CI, 1.03–1.20) for largest basal diameter, 1.23 (95% CI, 1.06–1.43) for square root–transformed MVD, and 1.51 (95% CI, 1.09–2.10) for presence of loops and networks, all of which independently contributed to prognosis.
CONCLUSIONS. The findings support the theory that both MVD and microvascular patterns contribute independently to prognosis in uveal melanoma in addition to cell type and size of the tumor.
This article has been cited by other articles:
|
|
 |
|
  R. Folberg, Z. Arbieva, J. Moses, A. Hayee, T. Sandal, S. Kadkol, A. Y. Lin, K. Valyi-Nagy, S. Setty, L. Leach, et al. Tumor Cell Plasticity in Uveal Melanoma: Microenvironment Directed Dampening of the Invasive and Metastatic Genotype and Phenotype Accompanies the Generation of Vasculogenic Mimicry Patterns Am. J. Pathol., October 1, 2006; 169(4): 1376 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Keilholz, P. Goldin-Lang, N. E. Bechrakis, N. Max, A. Letsch, A. Schmittel, C. Scheibenbogen, K. Heufelder, A. Eggermont, and E. Thiel Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction Clin. Cancer Res., March 1, 2004; 10(5): 1605 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Toivonen, T. Makitie, E. Kujala, and T. Kivela Microcirculation and Tumor-Infiltrating Macrophages in Choroidal and Ciliary Body Melanoma and Corresponding Metastases Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kivela and P. M. Grambsch Evaluation of Sampling Strategies for Modeling Survival of Uveal Malignant Melanoma Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3288 - 3293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.'a T. Al-Jamal, T. Makitie, and T. Kivela Nucleolar Diameter and Microvascular Factors as Independent Predictors of Mortality from Malignant Melanoma of the Choroid and Ciliary Body Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2381 - 2389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Clarijs, L. Schalkwijk, D. J. Ruiter, and R. M. W. de Waal EMAP-II Expression Is Associated with Macrophage Accumulation in Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 1801 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Walker, P. R. van Ginkel, R. L. Gee, H. Ahmadi, L. Subramanian, B. R. Ksander, L. F. Meisner, D. M. Albert, and A. S. Polans Expression of Angiogenic Factors Cyr61 and Tissue Factor in Uveal Melanoma Arch Ophthalmol, December 1, 2002; 120(12): 1719 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, A. J. Maniotis, D. Majumdar, J. Pe'er, and R. Folberg Uveal Melanoma Cell Staining for CD34 and Assessment of Tumor Vascularity Invest. Ophthalmol. Vis. Sci., August 1, 2002; 43(8): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]
|
|
|
|
|
|
R. Clarijs, I. Otte-Holler, D. J. Ruiter, and R. M. W. de Waal Presence of a Fluid-Conducting Meshwork in Xenografted Cutaneous and Primary Human Uveal Melanoma Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 912 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Makitie, O. Carpen, A. Vaheri, and T. Kivela Ezrin as a Prognostic Indicator and Its Relationship to Tumor Characteristics in Uveal Malignant Melanoma Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2442 - 2449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kivela, S. Eskelin, T. Makitie, and P. Summanen Exudative Retinal Detachment from Malignant Uveal Melanoma: Predictors and Prognostic Significance Invest. Ophthalmol. Vis. Sci., August 1, 2001; 42(9): 2085 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mäkitie, P. Summanen, A. Tarkkanen, and T. Kivelä Tumor-Infiltrating Macrophages (CD68+ Cells) and Prognosis in Malignant Uveal Melanoma Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1414 - 1421. [Abstract] [Full Text]
|
|
|
|
|
|
R. Clarijs, L. Schalkwijk, D. J. Ruiter, and R. M. W. de Waal Lack of Lymphangiogenesis Despite Coexpression of VEGF-C and Its Receptor Flt-4 in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1422 - 1428. [Abstract] [Full Text]
|
|
|
|
|
|
A. G. M. Scholes, S. Hagan, P. Hiscott, B. E. Damato, and I. Grierson Overexpression of Epidermal Growth Factor Receptor Restricted to Macrophages in Uveal Melanoma Arch Ophthalmol, March 1, 2001; 119(3): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Warso, A. J. Maniotis, X. Chen, D. Majumdar, M. K. Patel, A. Shilkaitis, T. K. Das Gupta, and R. Folberg Prognostic Significance of Periodic Acid-Schiff-positive Patterns in Primary Cutaneous Melanoma Clin. Cancer Res., March 1, 2001; 7(3): 473 - 477. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. G Sheidow, P. L Hooper, C. Crukley, J. Young, and J G. Heathcote Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis Br. J. Ophthalmol., July 1, 2000; 84(7): 750 - 756. [Abstract] [Full Text]
|
|
|
|
|
|
R. Folberg, M. J. C. Hendrix, and A. J. Maniotis Vasculogenic Mimicry and Tumor Angiogenesis Am. J. Pathol., February 1, 2000; 156(2): 361 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. McDonald, L. Munn, and R. K. Jain Vasculogenic Mimicry: How Convincing, How Novel, and How Significant? Am. J. Pathol., February 1, 2000; 156(2): 383 - 388. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
